Clinical trialNCT00509795CompletedPhase 3Interventional

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

SponsorRegeneron PharmaceuticalsEnrollment1,217Macular Degeneration

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Vitti, MD
Regeneron Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

188 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Facility name not stated
Calgary, Alberta, Canada
Facility name not stated
Vancouver, British Columbia, Canada
Facility name not stated
Victoria, British Columbia, Canada
Facility name not stated
Halifax, Nova Scotia, Canada
Facility name not stated
London, Ontario, Canada
Facility name not stated
Mississauga, Ontario, Canada
Facility name not stated
Ottawa, Ontario, Canada
Facility name not stated
Toronto, Ontario, Canada
Facility name not stated
Toronto, Ontario, Canada
Facility name not stated
Montreal, Quebec, Canada
Facility name not stated
Montreal, Quebec, Canada
Facility name not stated
Regina, Saskatchewan, Canada

United States

Facility name not stated
Birmingham, Alabama, United States
Facility name not stated
Birmingham, Alabama, United States
Facility name not stated
Phoenix, Arizona, United States
Facility name not stated
Phoenix, Arizona, United States
Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Beverly Hills, California, United States
Facility name not stated
Campbell, California, United States
Facility name not stated
Fullerton, California, United States
Facility name not stated
Glendale, California, United States
Facility name not stated
Irvine, California, United States
Facility name not stated
La Jolla, California, United States
Facility name not stated
Loma Linda, California, United States
Facility name not stated
Los Angeles, California, United States
Facility name not stated
Los Angeles, California, United States
Facility name not stated
Menlo Park, California, United States
Facility name not stated
Mountain View, California, United States
Facility name not stated
Oakland, California, United States
Facility name not stated
Palm Springs, California, United States
Facility name not stated
Pasadena, California, United States
Facility name not stated
Poway, California, United States
Facility name not stated
Sacramento, California, United States
Facility name not stated
San Diego, California, United States
Facility name not stated
San Francisco, California, United States
Facility name not stated
Santa Ana, California, United States
Facility name not stated
Torrance, California, United States
Facility name not stated
Ventura, California, United States
Facility name not stated
Westlake Village, California, United States

148 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aflibercept →Ranibizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2007
Primary completion: 30 Sept 2010
Completion: 31 Jul 2011
Last update posted: 28 Dec 2012
Registered enrollment: 1,217
Registry id: NCT00509795

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.